SYK Inhibitors, EHA Inauguration丨Dr. Bing Han: Innovative Dual Action of Syk Inhibitor Sovleplenib Promises New Frontiers in wAIHA Treatment
The European Hematology Association (EHA) annual meeting, an international conference in the field of hematology, gathers numerous experts and scholars from around the world to share and deeply discuss innovative ideas and scientific and clinical research advancements in hematology, promoting continuous development in the field. At this year's conference, the research results on spleen tyrosine kinase (SYK) inhibitors received significant attention. Sovleplenib (HMPL-523), the first SYK inhibitor from China (as of publication date) to apply for market approval, showcased its potential in treating hematological diseases at this EHA meeting. Oncology Frontier - Hematology Frontier has invited Dr. Bing Han from Peking Union Medical College Hospital to provide an in-depth interpretation of the research on Sovleplenib in the field of warm autoimmune hemolytic anemia (wAIHA), aiming to provide references for clinical practice.